This approval, granted under the expedited Commissioners National Priority Voucher (CNPV) program, brings a powerful new tool to the clinic
Following the hypothesis that GLP-1/Notch target genes most likely act redundantly, double RNAi with sygl-1 and other candidate target genes were performed (Kershner et al., 2014)
These development costs, combined with patent exclusivity that prevents generic competition until 2032, justify some premium pricing from the manufacturer's perspective
Individual results may vary depending on factors such as starting weight, dose, adherence, diet and exercise habits and how well the treatment is tolerated
Based on your goals, medical history, and research, our team prescribes your personalized treatment plan